The event marks the beginning of a key project, opening an important step in the journey of long-term cooperation, aiming to improve the quality of treatment for patients and contribute to improving the health care system in Vietnam.

At the event, representatives of FPT Long Chau and AstraZeneca Vietnam updated in-depth medical knowledge and consulting skills for pharmacists throughout the system, as well as raised awareness of health care among patients, thereby promoting compliance with treatment regimens, contributing to spreading practical values ​​to the community.

Representatives of Long Chau Pharmacy and AstraZeneca Vietnam at the event "10-year journey of DAPA in Vietnam"

The year 2025 marks a special milestone in the 10-year journey of the method using the active ingredient dapagliflozin, researched and produced by AstraZeneca, in the Vietnamese market. This therapy continues to be approved by the FDA (US Food and Drug Administration) for a new indication in the treatment of chronic kidney disease in addition to the two groups of type 2 diabetes and heart failure. (1) This medical advancement continues to affirm the outstanding value of a treatment solution capable of effectively affecting three chronic diseases that have a major impact on public health, including diabetes, heart failure and chronic kidney disease.

According to medical experts, cardiovascular - renal - metabolic diseases are closely related to each other, often exist simultaneously and can aggravate the remaining pathological condition. Therefore, the treatment of chronic kidney disease will not be for a single disease but requires simultaneous treatment and protection of all three diseases. Therefore, this direction also opens up opportunities to comprehensively improve the health of millions of patients, contributing to reducing the burden on the country's health system.

At the workshop, Mr. Atul Tandon - General Director of Astrazeneca Vietnam shared: " AstraZeneca's mission in the field of biopharmaceuticals is driven by a passion to understand and address patient needs, discover and develop innovative treatments, and strengthen close collaboration with local partners to improve the quality of life of patients. The partnership between AstraZeneca Vietnam and FPT Long Chau is a testament to this mission, as we work together to introduce innovative treatments and bring hope to the communities we serve."

Mr. Atul Tandon - General Director of AstraZeneca Vietnam

Ms. Nguyen Do Quyen, Deputy General Director of FPT Retail and CEO of FPT Long Chau Pharmacy and Vaccination System, expressed: "After 4 years of strategic cooperation, we are proud to join AstraZeneca Vietnam in implementing many community activities, training thousands of pharmacists and connecting with leading medical experts. Celebrating 10 years of DAPA in Vietnam today is an opportunity for us to look back on our development journey and shape our future strategy. With more than 16,000 pharmacists serving 26 million customers, FPT Long Chau is committed to continuing to be an extension of the healthcare industry, deeply accompanying AstraZeneca for a healthy Vietnam."

Ms. Nguyen Do Quyen, Deputy General Director of FPT Retail and Executive Director of FPT Long Chau Pharmacy and Vaccination System

Consistent with the aspiration to create a comprehensive healthcare ecosystem, Long Chau affirms the key role of the medical team and pharmacists, ensuring compliance with the criteria in consulting the right medicine - right disease - right dose, contributing to improving treatment compliance and comprehensive healthcare , Ms. Quyen further emphasized.

The program was attended by medical experts and pharmacists from Long Chau pharmacy.

Source: https://thanhnien.vn/fpt-long-chau-bat-tay-astrazeneca-viet-nam-cap-nhat-buoc-tien-y-hoc-3-trong-1-18525042814182034.htm